Action Calliditas Therapeutics Ab - 0A5R

Calliditas Therapeutics Ab (0A5R) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

( - )

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug...

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug...

Interim Report Q2, 2023: Calliditas Therapeutics

Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire STOCKHOLM, Aug. 17, 2023 Filing for full approval of TARPEYO STOCKHOLM, Aug. 17...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, May 30, 2023 STOCKHOLM, May 30, 2023...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0A5R - Frequently Asked Questions (FAQ)

What is the current Calliditas Therapeutics Ab share price?

The current share price of Calliditas Therapeutics Ab is SEK 0,00

What is the 1 year trading range for Calliditas Therapeutics Ab share price?

Calliditas Therapeutics Ab has traded in the range of SEK 0,00 to SEK 0,00 during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab (0A5R) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

0A5R Dernières nouvelles

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

Interim Report Q2, 2023: Calliditas Therapeutics

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

0A5R - Frequently Asked Questions (FAQ)

0A5R Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab (0A5R) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

0A5R Dernières nouvelles

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

Interim Report Q2, 2023: Calliditas Therapeutics

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

0A5R - Frequently Asked Questions (FAQ)

0A5R Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE